Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on September 26, 2022. The filing addresses significant changes in corporate leadership and governance effective immediately upon the Board of Directors' approval.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- Appointment of Interim Executive Chairman: Robert J. Bitterman, the existing Chairman of the Board, was appointed as Interim Executive Chairman.
- Departure of Interim Officers: Dr. Geert Cauwenbergh ceased serving as Interim Principal Executive Officer and Interim Principal Financial Officer, roles he held since May 4, 2022. He resumed his position as an independent Board member.
- Committee Resignations: Mr. Bitterman resigned from his roles as Chairman of the Compensation Committee and member of the Nominating Committee.
Compensation and Outlook
In connection with his new role, Mr. Bitterman's compensation package includes:
- Base Salary: An annual base salary of $175,000, which includes the $55,000 annual fee he previously received for Board service.
- Equity Grant: A one-time grant of 40,000 restricted stock units (RSUs) scheduled for October 1, 2022, vesting in full on the first anniversary of the grant date.
The filing does not provide specific guidance, outlook, or management commentary regarding the company's operational strategy or future financial performance beyond the leadership transition.
Investor Verification Checklist
- Verify the effective date of Dr. Cauwenbergh's departure from executive roles and the appointment of Mr. Bitterman.
- Confirm the vesting schedule and grant date for the 40,000 RSUs awarded to Mr. Bitterman.
- Review the press release dated September 29, 2022 (Exhibit 99.1) for additional context on the leadership transition.
- Check subsequent filings for the appointment of a permanent CEO and CFO, as the current roles are interim.